# US 2021/0079443 A1 · Indicator bacteriophage for selecting and monitoring for efficacy of therapeutics and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079443 A1
- Document ID: US20210079443A1
- Status: Published application
- Kind: A1
- Application number: 17/050,115
- Filed: 2019-04-24
- Published: 2021-03-18
- Earliest claimed: 2018-04-24
- Assignees: Laboratory Corporation of America Holdings
- Applicants: Laboratory Corporation of America Holdings
- Inventors: JOSE S. GIL; STEPHEN ERICKSON; MINH MINDY BAO NGUYEN; DWIGHT LYMAN ANDERSON
- Web page: https://patentgrep.com/patent/US20210079443A1

## CPC

- C12N 15/65: using markers (enzymes used as markers C12N15/52)
- C12Q 1/14: Streptococcus; Staphylococcus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12Q 1/66: involving luciferase
- C12Q 1/689: for bacteria
- C12N 2795/10131: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2795/10143: viral genome or elements thereof as genetic vector
- C12N 2795/10151: Methods of production or purification of viral material
- C12N 2800/202: of bacteriophage origin
- C12N 2840/203: having an IRES
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are methods and systems for detection of microorganisms in a sample and the utilization of such methods for selecting and monitoring therapies. The specificity of indicator bacteriophage, such as Staphylococcus-specific bacteriophage, allows detection of a specific microorganism, such as Staphylococcus and the indicator signal may be amplified to optimize assay sensitivity.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 2

A method for detecting Staphylococcus in a sample comprising:
incubating the sample with a recombinant bacteriophage derived from Staphylococcus-specific bacteriophage comprising an indicator gene inserted into a late gene region of the bacteriophage genome; and
detecting an indicator protein product produced by the recombinant bacteriophage, wherein positive detection of the indicator protein product indicates that Staphylococcus is present in the sample,
wherein incubating the sample with the recombinant bacteriophage is performed at a temperature of at least about 25 degrees Celsius (C) and no greater than about 45 degrees C.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Staphylococcus is Staphylococcus aureus.

### Claim 4 (depends on 3)

The method of claim 3, wherein the Staphylococcus aureus is methicillin-resistant.

### Claim 5 (depends on 2)

The method of claim 2, wherein the sample is a food, environmental, water, commercial, or clinical sample.

### Claim 6 (depends on 2)

The method of claim 2, wherein the method detects as few as 10, 9, 8, 7, 6, 5, 4, 3, 2, or a single bacterium in a sample of a standard size for the food safety industry.

### Claim 7 (depends on 5)

The method of claim 5, wherein the food sample comprises meat, fish, vegetables, eggs, or powdered infant formula.

### Claim 8 (depends on 2)

The method of claim 2, wherein the sample is incubated with a cocktail composition comprising at least two different types of recombinant bacteriophages, wherein at least one of the recombinant bacteriophages comprises an indicator gene according to claim 2.

### Claim 9 (depends on 2)

The method of claim 2, wherein the sample is first incubated in conditions favoring growth for an enrichment period of 9 hours or less, 8 hours or less, 7 hours or less, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less.

### Claim 10 (depends on 2)

The method of claim 2, wherein the total time to results is less than 12 hours, less than 11 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, or less than 6 hours.

### Claim 11 (depends on 2)

The method of claim 2, wherein the ratio of signal to background generated by detecting the indicator is at least 2.0 or at least 2.5.

### Claim 12

A system for detecting Staphylococcus comprising a recombinant bacteriophage derived from Staphylococcus-specific bacteriophage.

### Claim 13 (depends on 12)

The system of claim 12, wherein the Staphylococcus is Staphylococcus aureus and the Staphylococcus-specific bacteriophage is Staphylococcus aureus-specific bacteriophage.

### Claim 14 (depends on 13)

The system of claim 13, wherein the Staphylococcus aureus is methicillin-resistant and the Staphylococcus aureus-specific bacteriophage is methicillin-resistant Staphylococcus aureus-specific bacteriophage.

### Claim 15 (depends on 12)

The system of claim 12, further comprising a substrate for reacting with an indicator to detect the soluble protein product expressed by the recombinant bacteriophage.

### Claim at position 16

-32. (canceled)

### Claim 17

A method for selecting a treatment for a subject comprising:
(i) obtaining a biological sample from the subject;
(ii) detecting a specific microorganism or category of microorganisms in the biological sample using an indicator phage; and
(iii) selecting a treatment based on the identity of a specific microorganism detected in the biological sample.

### Claim 18 (depends on 17)

The method of claim 17, wherein the indicator phage is a synthetically prepared phage.

### Claim 19 (depends on 17)

The method of claim 17, wherein the indicator phage is a genetically modified naturally occurring phage.

### Claim 20

(canceled)

### Claim 21 (depends on 2)

The method of claim 2, wherein incubating the sample with the recombinant bacteriophage is performed at a temperature of about 37 degrees C.

### Claim 22 (depends on 2)

The method of claim 2, wherein the indicator protein product is a luciferase enzyme.

### Claim 23 (depends on 2)

The method of claim 2, wherein prior to incubating with the sample, the recombinant bacteriophage is purified to remove any residual indicator protein product generated during production, such that the recombinant bacteriophage is substantially free of indicator protein product.
